HK1220607A1 - 晚期糖化终产物(age)前体的螯合剂 - Google Patents

晚期糖化终产物(age)前体的螯合剂 Download PDF

Info

Publication number
HK1220607A1
HK1220607A1 HK16108617.8A HK16108617A HK1220607A1 HK 1220607 A1 HK1220607 A1 HK 1220607A1 HK 16108617 A HK16108617 A HK 16108617A HK 1220607 A1 HK1220607 A1 HK 1220607A1
Authority
HK
Hong Kong
Prior art keywords
sequestrants
age
precursors
end product
advanced glycation
Prior art date
Application number
HK16108617.8A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus BESEV
Robert J. Miller
Andrew T. Papoulis
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of HK1220607A1 publication Critical patent/HK1220607A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
HK16108617.8A 2013-03-15 2014-03-12 晚期糖化终产物(age)前体的螯合剂 HK1220607A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
US61/792,719 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
HK1220607A1 true HK1220607A1 (zh) 2017-05-12

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108617.8A HK1220607A1 (zh) 2013-03-15 2014-03-12 晚期糖化终产物(age)前体的螯合剂

Country Status (24)

Country Link
US (2) US20160024233A1 (enExample)
EP (1) EP2968403A1 (enExample)
JP (4) JP2016512830A (enExample)
KR (1) KR20150130492A (enExample)
CN (1) CN105188718A (enExample)
AR (1) AR095593A1 (enExample)
AU (2) AU2014235500A1 (enExample)
BR (1) BR112015023404A8 (enExample)
CA (1) CA2906501A1 (enExample)
CL (1) CL2015002624A1 (enExample)
CR (1) CR20150545A (enExample)
DO (1) DOP2015000221A (enExample)
EA (1) EA201591733A1 (enExample)
HK (1) HK1220607A1 (enExample)
IL (1) IL241406A0 (enExample)
MA (1) MA38487A1 (enExample)
MX (1) MX2015012843A (enExample)
PE (1) PE20151766A1 (enExample)
PH (1) PH12015502019A1 (enExample)
SG (2) SG11201506413PA (enExample)
TN (1) TN2015000390A1 (enExample)
TW (1) TW201521744A (enExample)
UY (1) UY35441A (enExample)
WO (1) WO2014150873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112020003638A2 (pt) * 2017-08-31 2020-09-01 Cytosorbents Corporation redução de produtos finais de glicação avançada a partir de fluidos corporais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
ES2637020T3 (es) * 2001-04-18 2017-10-10 Genzyme Corporation Uso de polímero de amina para reducir la glucosa sérica
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
JP2007523908A (ja) * 2004-02-17 2007-08-23 ダイナミス セラピューティクス インコーポレイテッド フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US9181364B2 (en) * 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
CR20150545A (es) 2015-12-01
SG11201506413PA (en) 2015-09-29
EP2968403A1 (en) 2016-01-20
JP2018135365A (ja) 2018-08-30
PH12015502019A1 (en) 2016-01-11
BR112015023404A2 (pt) 2017-07-18
BR112015023404A8 (pt) 2019-12-03
CA2906501A1 (en) 2014-09-25
MX2015012843A (es) 2016-08-08
AU2014235500A1 (en) 2015-11-05
US20160024233A1 (en) 2016-01-28
EA201591733A1 (ru) 2016-01-29
KR20150130492A (ko) 2015-11-23
CN105188718A (zh) 2015-12-23
TN2015000390A1 (en) 2017-01-03
PE20151766A1 (es) 2015-12-11
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
CL2015002624A1 (es) 2016-03-11
US20180265613A1 (en) 2018-09-20
MA38487A1 (fr) 2017-12-29
DOP2015000221A (es) 2015-12-15
JP2022037143A (ja) 2022-03-08
JP2020055850A (ja) 2020-04-09
AR095593A1 (es) 2015-10-28
JP2016512830A (ja) 2016-05-09
IL241406A0 (en) 2015-11-30
WO2014150873A1 (en) 2014-09-25
UY35441A (es) 2014-10-31
AU2019201259A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
HK1219483A1 (zh) 包含杂芳族环-苄基-酰胺-环核心的自分泌运动因子抑制剂
IL236123A0 (en) Preparations containing n-[4,2-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4,1-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cftr-mediated disorders
HK1211231A1 (en) Exendin-4 derivatives
WO2014097151A3 (en) Autotaxin inhibitors
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
HK1206028A1 (en) Phenicol antibacterials
SMT201600151B (it) Nuovi composti bisostituiti di 3, 4-diammino-3-ciclobuten-1, 2-dione utili nel trattamento di patologie mediate da chemiochine
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
BR112016007536A8 (pt) compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias
EP3098224A4 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
HK1245117A1 (zh) 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MY161578A (en) Composition for reducing absorption of dietary fat
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
HK1218715A1 (zh) 活化的大豆豆荚纤维
HK1201477A1 (en) Pharmaceutical composition of omeprazole
WO2017079403A3 (en) Polymeric nanoparticles
PH12015502019A1 (en) Sequestrants of advanced glycation end product (age) precursors
WO2013100718A3 (ko) 라저스트로에미아 오바리폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 질환 또는 천식의 예방 또는 치료용 약학적 조성물
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2013029634A3 (es) Composición antioxidante, antigripal natural
MX2017006270A (es) Compuestos de 1,2-benzotiazol para el tratamiento de transtornos renales.
CN301991818S (zh) 家具连接件（易系列）
AU2013904443A0 (en) Dietary supplement for the treatment of acid reflux and gastro-oesophageal reflux disease (gord/gerd)